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Abstract
SEMA3F is a secreted semaphorin with potent antitumor activity, which is frequently downregulated in lung can-
cer. In cancer cell lines, SEMA3F overexpression decreases hypoxia-induced factor 1α protein and vascular endo-
thelial growth factor mRNA, and inhibits multiple signaling components. Therefore, understanding how SEMA3F
expression is inhibited in cancer cells is important. We previously defined the promoter organization of SEMA3F
and found that chromatin remodeling by a histone deacetylase inhibitor was sufficient to activate SEMA3F expres-
sion. In lung cancer, we have also shown that ZEB-1, an E-box transcription repressor, is predominantly respon-
sible for loss of E-Cadherin associated with a poor prognosis and resistance to epidermal growth factor receptor
inhibitors. In the present study, we demonstrated that ZEB-1 also inhibits SEMA3F in lung cancer cells. Levels of
ZEB-1, but not ZEB-2, Snail or Slug, significantly correlate with SEMA3F inhibition, and overexpression or inhi-
bition of ZEB-1 correspondingly affected SEMA3F expression. Four conserved E-box sites were identified in the
SEMA3F gene. Direct ZEB-1 binding was confirmed by chromatin immunoprecipitation assays for two of these,
and ZEB-1 binding was reduced when cells were treated with a histone deacetylase inhibitor. These results dem-
onstrate that ZEB-1 directly inhibits SEMA3F expression in lung cancer cells. SEMA3F loss was associated with
changes in cell signaling: increased phospho-AKT in normoxia and increase of hypoxia-induced factor 1α protein
in hypoxia. Moreover, exogenous addition of SEMA3F could modulate ZEB-1–induced angiogenesis in a chorioal-
lantoic membrane assay. Together, these data provide further support for the importance of SEMA3F and ZEB-1 in
lung cancer progression.
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Introduction
SEMA3F was originally cloned from a recurrent 3p21.3 homozygous
deletion in small cell lung carcinoma (SCLC), suggesting that it
might be a tumor suppressor gene [1–3]. Class-3 semaphorins [4], in-
cluding SEMA3F, are secreted proteins originally identified as media-
tors of growth cone repulsion [5], but their wide expression patterns
suggested additional functions outside the nervous system [6]. Their
involvement in cancer and angiogenesis was further described (see
recent reviews [7–10]). Exogenous expression of SEMA3F in tumor
cell lines reduced tumor formation in nude mice in several xenograft
models [11–15]. The resulting tumors displayed a reduced density of
blood vessels, implying that SEMA3F inhibits angiogenesis during
tumor development. In addition, the SEMA3F-expressing tumor in-
duced less metastases [11]. One possible explanation for the anti-
angiogenic activity of SEMA3F has been a competition between
SEMA3F and vascular endothelial growth factor 165 (VEGF165)
for binding to their common neuropilin receptor, as was shown for
Sema3A [16].
Using a lung orthotopic model, we reported that SEMA3F blocked
H157 lung cancer tumorigenesis [17]. This was associated with a
SEMA3F-induced loss of activated αVβ3 integrin and impaired cell
adhesion to extracellular matrix components [14,17]. Several signaling
pathways were affected by SEMA3F, including decreased phospho-
extracellular signal–regulated kinase 1/2, phospho-AKT, phospho–
signal transducer and activator of transcription 3, and down-regulation
of integrin-linked kinase activity [14]. In addition, SEMA3F nega-
tively affected the level of hypoxia-induced factor 1α (HIF-1α) pro-
tein and, as a consequence, VEGF mRNA expression [14]. Therefore,
we proposed a second explanation for the antiangiogenic effect of
SEMA3F, i.e., VEGF165 down-regulation owing to HIF-1α loss. This
effect is in accordance with our observations that SEMA3F is down-
regulated in a majority of human lung cancers and that loss of SEMA3F
protein staining is significantly correlated with an advanced stage of
disease and with VEGF165 overexpression [18].
Although SEMA3F is frequently downregulated in tumors, inacti-
vating mutations have not been observed [15]. Therefore, it is impor-
tant to understand how SEMA3F is regulated. Presently, little is
known about SEMA3F regulation except that SEMA3F is a direct
p53 target [12], and we reported that DNA methylation and chro-
matin remodeling by histone deacetylase inhibitors (HDACis) play a
role in SEMA3F expression [19].
Previously, we defined the genomic organization of the SEMA3F
promoter [19]. We identified several putative E-box sites (consensus
palindromic sequence CANNTG) present in the SEMA3F promoter,
as well as in introns 1 and 3. These sites bind basic helix-loop-helix
proteins and other transcription factors with zinc fingers including
ZEB-1, ZEB-2, Snail, and Slug, among others. We previously demon-
strated that blocking ZEB-1 (also known as TCF8 and δEF1) with
small interfering RNA (siRNA) in H661 lung cancer cells led to
the up-regulation of E-Cadherin [20]. In addition, we reported that
ZEB-1 expression and E-Cadherin loss are associated with resis-
tance to epidermal growth factor receptor (EGFR) inhibitors and
a poor prognosis in lung cancer [21,22]. ZEB-1 promotes tumor
cell dedifferentiation with repression of regulators of epithelial polar-
ity and is involved in metastasis [23–25]. ZEB-1 like ZEB-2 (also
known as ZFXH1B and SMAD interacting protein 1 known as SIP1)
have emerged as key factors that regulate induction of the epithelial-
mesenchymal transition (EMT) playing a critical role in tumor pro-
gression, invasion, and metastasis [26–28]. Epithelial-mesenchymal
transition is associated with E-Cadherin repression by direct ZEB-1
binding to E-Cadherin regulatory sequences. This regulation is facili-
tated by ZEB-1 interaction with the transcriptional corepressor CtBP,
which can recruit HDACs leading to chromatin condensation [29–
33]. Therefore, ZEB-1 could be a potential candidate for SEMA3F
repression in lung cancer.
In the present study, we demonstrated that ZEB-1 levels are sig-
nificantly correlated with down-regulation of SEMA3F in lung can-
cer cells. This negative correlation was verified by up-regulation or
inhibition of ZEB-1. In addition, ZEB-1 binds to regulatory E-box
sites in the SEMA3F gene, and this binding is impaired by HDACi.
Furthermore, SEMA3F loss is associated with changes in cell signaling.
When SEMA3F is added back after depletion by ZEB-1, it decreases
ZEB-1–induced angiogenesis. In addition to providing a better un-
derstanding of SEMA3F regulation, these results support the impor-
tance of SEMA3F and ZEB-1 in lung cancer progression.
Materials and Methods
Cell Lines and Culture
A panel of 21 non–small cell lung carcinoma (NSCLC) cell lines,
including NCI-H661 and NCI-H358 cell lines, were grown in
RPMI-1640 supplemented by 10% fetal calf serum (Invitrogen, Cergy
Pontoise, France). All the cell lines were previously described [21].
MCF7 breast cancer cells were grown in the same conditions. For
HDAC inhibition, H661 cells were treated with 5 μM suberoylanilide
hydroxamic acid (SAHA) for 16 hours before harvesting.
Transient Transfection Assays
Two micrograms of pCS2MT and pCS2MT–ZEB-1 plasmids
(kindly provided by Dr. J. Richter) were transfected using 3 μl of
Fugene (Roche Applied Sciences, Meylan, France) into 0.5 × 105
H661 cells plated 24 hours before transfection. Cells were harvested
at 24, 48, 72, or 96 hours after transfection. Each transfection was
tested in two independent experiments.
Stable Transfections
Establishment of H358 cell line with stably integrated ZEB-1, under
the control of a tetracycline/doxycycline (Dox)–inducible promoter,
was obtained following the Flip-In T-REX core kit instructions
(Invitrogen). ZEB-1 was cloned with a 6 Myc tag at the 3′end, into
the EcoRV restriction site of pcDNA5/FRT/TO plasmid (Invitrogen).
H358 cells transfected with empty vector (H358 FlpIn EV) or in-
ducible ZEB-1 (H358 FlpIn ZEB-1) were selected with 100 μg/ml
hygromycin and 5 μg/ml blasticidin (Invitrogen). ZEB-1 was induced
for 3 days with Dox at 200 ng/ml.
Luciferase Reporter Assays
The SEMA3F promoter fragment [−5836 to −4013] relative to the
start codon at position +1 was amplified by polymerase chain reaction
(PCR) and cloned upstream of the Firefly luciferase gene in the
pGL3basic vector (Promega, Charbonnières-les-Bains, France). For
that purpose, XhoI and HindIII restriction sites were included in the
primers described in Table W1E . Cloning was performed as previously
described [19]. This construct (2 μg) was transfected into MCF7 and
H661 cells with Fugene (Roche Applied Sciences). In each experiment,
the pRL-TK plasmid (100 ng), encoding Renilla luciferase (Promega),
was cotransfected to measure transfection efficiency and for normaliza-
tion purposes. Luminescence was measured 48 hours after transfection
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using the Dual-Luciferase Reporter Assay System (Promega). The
pGL3basic (promoterless) plasmid was used in each experiment to de-
termine luciferase basal level. Reporter activity was normalized by cal-
culating the ratio of Firefly/Renilla values. Each construct was tested in
two independent transfections, each time in duplicate.
Site-Directed Mutagenesis
The bipartite element of the E-Box site in the SEMA3F promoter
fragment was mutated using the Quick Change Site-Directed Muta-
genesis Kit (Stratagene, Amsterdam, the Netherlands) following the
protocol provided by the manufacturer except for the PCR condi-
tions. Because the GC content is very high (82% GC) in this frag-
ment, PCR was performed with the Platinum Pfx DNA polymerase
(Invitrogen) with the recommended enhancer buffer. Primers are de-
scribed in Table W1D.
Small Interfering RNA Transfection
To inhibit ZEB-1 expression, RNA interference inhibition was per-
formed as described [20,34]. Double-stranded RNA oligonucleotides
were prepared by using the Silencer kit from Ambion (Austin, TX).
Primer sequences [20] are given in Table W1C . H661 cells (1 × 105)
were transfected with 5, 50, or 100 nM of double-stranded RNA
by Oligofectamine (Invitrogen). Controls were mock-transfected
cells. H661 cells were transfected with 50 nM siRNA against
SEMA3For nontargeting siRNA fromDharmacon (Brebieres, France;
Table W1C ; Reference Genome Smart pool M-0176644-02 and
D-001210-02, respectively). Cells were harvested 48 hours after trans-
fection. Each concentration of siRNA was tested in three indepen-
dent experiments.
RNA Expression
Total RNA was extracted using the SV Total RNA isolation kit
(Promega). Reverse transcription–PCR (RT-PCR) was performed
with the Superscript II reverse transcriptase (Invitrogen) using the pro-
cedure supplied by the manufacturer. We assessed levels of SEMA3F,
ZEB-1, ZEB-2, or E-Cadherin mRNA relative to GAPDH in cell lines
by quantitative real-time PCR using the GeneAmp 7000 quantitative
PCR system (Applied Biosystems, Courtaboeuf, France) with SYBR-
Green chemistry [17]. The RT-PCRprimers are described in TableW1A.
The results are displayed in the relative expression (×100) compared to
GAPDH expression.
Immunoblot Analysis
Immunoblots were done as reported previously [14,17]. The anti-
Myc and anti–α tubulin were from Sigma-Aldrich (Saint Quentin
Fallavier, France) and used at 1:2000 dilution. Anti–ZEB-1 (1:1000)
was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-AKT
and anti–phospho-Ser473-AKTwere from Cell Signaling Technology
(Danvers, MA) and used at 1:1000 dilution. Anti–HIF-1α (1:250)
was from BD Transduction Laboratories (Erembodegem, Belgium).
Horseradish peroxidase–conjugated antimouse and antirabbit second-
ary antibodies (1:5000) were from Perkin-Elmer (Courtaboeuf, France).
Detection was done with enhanced chemiluminescence (Perkin-Elmer).
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assay was performed
with the protocol described by Upstate (Millipore, Saint Quentin
en Yvelines, France) with modifications for the last washes. Briefly,
5 × 106 cells per assay were cross-linked with 1% formaldehyde at
37°C for 5 minutes. Cells were resuspended in the SDS lysis buffer
[1% SDS, 10 mM EDTA, 50 mMTris-HCl (pH 8.1)] for 15 minutes
on ice. The lysate was sonicated 10 times, 15 seconds on ice. After
centrifuging at 13,000 rpm at 4°C for 10 minutes, the supernatant
was diluted 10 times in the dilution buffer [0.01% SDS, 1.1% Triton
X-100, 1.2 mMEDTA, 167mMNaCl, 16.7 mMTris-HCl (pH 8.1)]
and was incubated for 1 hour on a rotating platform at 4°C with
Protein-A Sepharose. One microgram of ZEB-1 antibodies (H102;
Santa Cruz Biotechnology) or of IgG from a nonimmunized rabbit
(i5006; Sigma) was incubated with the precleared chromatin on a ro-
tating platform, overnight at 4°C. Immune complexes were collected
with Protein-A Sepharose (Amersham, GEHealthcare, Orsay, France).
They were washed three times with the LiCl Buffer [0.25 M LiCl, 1%
Triton X-100, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-HCl
(pH 8.1)] and twice with the TE buffer [1 mM EDTA, 10 mM Tris-
HCl (pH 8)] before phenol–chloroform extraction and ethanol precip-
itation. Quantitative real-time PCR was performed with SYBR-Green
chemistry with primers described in TableW1B. For each PCR primer
set, Ct values were obtained for purified DNA from the input, and
ZEB-1 and IgG immunoprecipitated chromatin. Then, we determined
ΔCtZEB-1 = CtZEB-1 − Ctinput and ΔCtIgG = CtIgG − Ctinput. The fold en-
richment is obtained by the ratio 2−ΔCtZEB-1/2−ΔCtIgG. The percentage
of input is shown in Figure W1 (B and C ).
Chorioallantoic Membrane Assay
Fertilized Hubbard JA57 chick eggs were incubated under condi-
tion of constant humidity (70%) at 37.8°C. On the fourth day of in-
cubation, a square window was opened in the shell after removal of
2.5 ml of albumin to detach the chorioallantoic membrane (CAM)
from the shell. The window was closed with tape, and the eggs were
returned to the incubator. At day 9, a pellet of 5 × 105 cells resus-
pended in an equivalent volume of Matrigel (BD Biosciences, Le Pont
de Claix, France) was implanted on top of growing CAMs. For ZEB-1
induction, cells were grown with 0.2 μg/ml Dox for 10 days before
implantation. To maintain ZEB-1 induction, 0.5 μg/ml Dox was
added in Matrigel the day of implantation. Where indicated, recom-
binant mouse SEMA3F-Fc (RD Systems, Lille, France) was delivered
at 0.7 pmol per plug. Blood vessels on the CAMwere examined 6 days
after cell implantation and photographed in ovo under a Nikon SMZ
1500 Microscope with a Nikon NS Fi1 camera (Nikon, Champigny
sur Marne, France). Each egg was assigned a score number varying
from 0 to 3, in which 0 is the no angiogenic response and 3 is the stron-
gest response (Figure 5D). Blinded scoring was performed simulta-
neously by two observers. The mean was calculated by GraphPad
Prism (version 5.01; GraphPad Software Incorporation, La Jolla, CA),
and a nonparametric Kruskal-Wallis statistical test was performed.
Results
ZEB-1 Expression Is Negatively Correlated with
SEMA3F in Lung Cancer Cell Lines
Using quantitative real-time RT-PCR, we screened 21 NSCLC cell
lines for expression of SEMA3F, ZEB-1, and three additional E-box
transcriptional repressors, ZEB-2, Snail, and Slug. ZEB-1 expression
had a significant negative correlation with SEMA3F (Spearman corre-
lation coefficient, r = −0.57, P = .0089; Figure 1). In contrast, no sta-
tistically significant correlations were observed between the expression
of SEMA3F and ZEB-2, Snail, or Slug, nor were there any apparent
trends (not shown).
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ZEB-1 Induces Transcriptional Down-regulation of
SEMA3F in the H661 NSCLC Cell Line
To determine whether ZEB-1 could regulate SEMA3F expression,
H661 cells were transiently transfected with a Myc-tagged ZEB-1
expression construct. We first verified ZEB-1 expression by quantita-
tive real-time RT-PCR and observed a 100-fold enrichment in expres-
sion (Figure 2A, top left). Western blot analysis using anti–ZEB-1
antibodies detected ZEB-1 protein in transfected cells (Figure 2A,
top right). As a positive control, we examined E-Cadherin expression
for two reasons: 1) ZEB-1 has been shown to bind E-box sites in the
E-Cadherin promoter and to inhibit its expression; and 2) we previ-
ously demonstrated that blocking ZEB-1 with small interfering RNA
(siRNA) in H661 cells led to up-regulation of E-Cadherin [20].
Indeed, 48 hours after ZEB-1 transfection, E-Cadherin mRNA was
reduced to 40% (Figure 2A, bottom left) along with a 50% decrease
for SEMA3F mRNA level at 72 hours (Figure 2A, bottom right). We
noticed that E-Cadherin expression seemed to be still inhibited after
96 hours (however, the expression was not statistically different from
the control), but SEMA3F was not. We believe that increasing ZEB-1
could modify ZEB-1 coregulator expression or other transcriptional
factors affecting differently E-Cadherin and SEMA3F expression over
Figure 1. ZEB-1 expression is negatively correlated with SEMA3F
in lung cancer cell lines. ZEB-1 (white bars) and SEMA3F (black bars)
mRNA were measured by quantitative real-time RT-PCR in 21 lung
cancer cell lines. Values are expressed as percentage of GAPDH
expression. Because the variables are not normally distributed, we
used the Spearman correlation coefficient (a nonparametric analog
to the Pearson correlation coefficient) for statistical analysis.
Figure 2. ZEB-1 downregulates SEMA3F transcription in H661 cells. (A) H661 cells were transiently transfected with control (CTL; black
bars) or ZEB-1 expression vector (ZEB-1; white bars) and were harvested over time to measure ZEB-1, E-Cadherin, and SEMA3F expres-
sions by quantitative real-time RT-PCR. Values are expressed in percentage of GAPDH expression. ZEB-1 protein was checked by West-
ern blot analysis at 48 hours after transfection (top right). α-Tubulin was used as a loading control. The low E-Cadherin mRNA level in
H661 cells is in accordance with previous results where H661 cells were selected among NSCLC for their undetectable E-Cadherin [20].
Reasons of the absence of E-Cadherin are the loss of Wnt7a/β-catenin pathway and ZEB-1 expression. (B) H661 cells were transfected
with different amounts of ZEB-1 siRNA. ZEB-1, ZEB-2, E-Cadherin, and SEMA3F mRNA were monitored 48 hours after transfection.
Values for three independent experiments (except for ZEB-2), done in duplicate, are expressed in percentage of GAPDH expression.
Bars, SD. Statistical analysis was performed with Student’s t-test: *P < .05, **P < .01.
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time. To verify the relationship between endogenous ZEB-1 and
SEMA3F, we used siRNA to inhibit ZEB-1 in H661 cells (Figure 2B).
Compared with mock-transfected cells, the level of ZEB-1 mRNA
was lowered by 50%, whereas E-Cadherin and SEMA3F expression
increased accordingly. E-Cadherin and SEMA3F expressions seemed
to be stimulated with ZEB-1 siRNA at very different concentra-
tions (5 and 50 nM, respectively). Because we did not check siRNA
concentrations between 5 and 50 nM, we cannot say that 10 times
more siRNA were necessary to activate SEMA3F compared to E-
Cadherin. In contrast, the expression of a nontarget gene, such as
ZEB-2, was unaffected.
ZEB-1 Directly Binds E-box Sites in SEMA3F in H661
Cells and HDACi Inhibits This Binding
Four evolutionarily conserved E-box sites are present in the 5′ se-
quence of SEMA3F (Figure 3A). Site 1 is located within the CpG
island promoter region, site 2 is in the first intron, and sites 3 and 4
are located within the third intron. Sites 1, 2, and 4 are bipartite
elements, which have been reported to bind ZEB-1 in other target
genes [35]. Direct in vivo analysis of ZEB-1 binding to these sites
was carried out using ChIP assays, and changes in ZEB-1 binding were
ascertained by quantitative real-time PCR. Chromatin immuno-
precipitation assays were performed with IgG from a nonimmunized
Figure 3. ZEB-1 binds directly to SEMA3F promoter and HDAC inhibition represses this binding in H661 cells. (A) Genomic organization
of the SEMA3F promoter. Transcription start sites (TSS) are indicated by arrows. White oval indicates the CpG island, and black boxes
indicate exons. Four putative E-box sites, numbered 1 to 4 (indicated by white stars) were predicted by computer analysis using Mulan
and multiTF at NCBI DCODE.org (www.dcode.org) [51]. Horizontal black bars show the position of PCR products after ChIP experiments,
with their name (A to F) indicated above. The SEMA3F promoter fragment [−5836 to −4013] tested in the luciferase reporter construc-
tion is indicated below. (B) Chromatin immunoprecipitation assays were done on H661 cells grown 16 hours in the absence (black bars)
or in the presence (white bars) of 5 μM SAHA. E-Cadherin and Alu PCR, respectively, were used as positive and negative ChIP controls.
The results of quantitative real-time PCR are expressed by fold enrichment, for three independent experiments with PCR reactions being
performed in duplicate. Bars, SD. Semiquantitative analysis of PCR products obtained after ChIP assays was performed by electropho-
resis on agarose gel after 30 cycles for Alu PCR and 33 cycles for all the other PCR. (C) ZEB-1, E-Cadherin, and SEMA3F mRNA levels
were measured by quantitative real-time RT-PCR on H661 cells grown 16 hours in the absence (black bars) or in the presence (white
bars) of 5 μM SAHA. This experiment was done three times, and each RT-PCR in duplicate. Values are expressed in percentage of
GAPDH expression. Bars, SD. (D) The luciferase reporter constructions, with the [−5836 to−4013] SEMA3F promoter fragment, mutated
or not (WT) for each or both elements of the E-box site 1 present in this fragment, were transfected into MCF7 and H661 cells. Firefly lu-
ciferase activity was measured and normalized to the Renilla luciferase activity of the cotransfected plasmid pRL-TK for two independent
experiments done in duplicate. Bars, SD. Statistical analysis was performed with Student’s t-test: *P < .05, **P < .01.
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rabbit as a negative control. As a positive control, ZEB-1 binding was
verified on the E-Cadherin promoter, and ZEB-1 overexpression
was associated with a three-fold enrichment as expected (Figure 3B,
black bars). The presence of PCR products was confirmed by electro-
phoresis (Figure 3B). In contrast, no enrichment was evident with
Alu sequences used as a negative control. For SEMA3F, two of the four
predicted E-box sites (i.e., sites 1 and 4) bound ZEB-1 (Figure 3B,
black bars). Of note, site 1 is located in the CpG island approximately
300 bp from the experimentally determined transcriptional start sites
[19]. To assess nonspecific binding, ChIP assays were performed for
two E-box–negative regions located in intron 3 (product C) and intron
13 (product F; Figure 3A). As expected, no enrichment was noticed
(Figure 3B, black bars).
We previously reported that treatment of H460 NSCLC cells by
Trichostatin A (TSA), an HDACi, induced SEMA3F expression [19].
As it is known that ZEB-1 recruits CtBP which can interact with
HDACs [29–33] and because HDACis influence protein complexes
on regulatory DNA sequences [36], we determined whether SAHA
(vorinostat) treatment would cause ZEB-1 to dissociate from SEMA3F
E-box sites. To examine ZEB-1 binding after treatment with an
HDACi, we exposed H661 cells to 5 μM SAHA during 16 hours
and first verified that SEMA3F and E-Cadherin mRNAwere increased
(≈4.3-fold and ≈7-fold, respectively) as anticipated (Figure 3C). In these
conditions, the level of ZEB-1 mRNAwas unaffected. By a ChIP assay,
the binding of ZEB-1 to the E-Cadherin promoter was decreased
(Figure 3B, white bar). Similarly, ZEB-1 dissociated completely from
SEMA3F site 4, and its binding to site 1 was greatly decreased. These
results support the direct binding of ZEB-1 in the transcriptional repres-
sion of SEMA3Fand demonstrate that ZEB-1 dissociates from SEMA3F
gene sequences after treatment with an HDACi.
Because site 1 is a bipartite element, located in the regulatory se-
quence in the CpG island, it seems to be an important regulatory
sequence. To test this hypothesis, we performed a luciferase reporter
assay by cloning the [−5836 to −4013] SEMA3F promoter fragment
that contains site 1 and we introduced mutations of each part of the
bipartite element separately (mut1, mut2) or together (mut1-2).
These constructs were transfected into MCF7 breast cancer cells,
chosen only as a positive control in this gene reporter assay because
we previously demonstrated that the SEMA3F promoter fragment
[−6310 to −4013] and [−5836 to −4013] are functional in these cells
[19] (and data not shown). In addition, MCF7 cells express a high
level of SEMA3F but almost no ZEB-1. The expressions of SEMA3F
and ZEB-1 in H661 and MCF7 cells displayed in the relative expres-
sion (×100) compared to GAPDH expression were the following:
SEMA3F = 0.7%, ZEB-1 = 0.2% in H661 cells and SEMA3F =
4.7%, ZEB-1 = 0.005% in MCF7 cells. Each mutation separately
or in combination did not modify luciferase activity in MCF7 cells
when compared to the wild type sequence (Figure 3D). In contrast,
these mutations increased luciferase activity (≈2.5-fold) in H661 cells
(Figure 3D). This reporter gene assay shows that site 1 is necessary to
repress SEMA3F in H661 cells.
Tet-Induced ZEB-1 Binds SEMA3F
E-box Sites in H358 Cells
To demonstrate that ZEB-1 inhibition of SEMA3F was not limited
to H661 cells, we engineered the H358 NSCLC cell line with the tet-
inducible FlpIn system (Invitrogen) and introduced a 6 Myc-tagged
ZEB-1 into the homologous recombination site. After 3 days of Dox
induction (200 ng/ml), ZEB-1 mRNA was induced approximately
eight-fold compared to noninduced or control cells containing an empty
vector (Figure 4A). ZEB-1 protein was detected by Western blot with
either ZEB-1 orMyc antibodies (Figure 4B). As expected, ZEB-1 induc-
tion was associated with a reduction in E-Cadherin mRNA (Figure 4A).
Similarly, SEMA3F mRNA levels were reduced to approximately 50%
of controls (Figure 4A). SEMA3F protein could not be detected because
the commercial SEMA3F antibody (Chemicon, Hants, England) was
raised against a peptide that corresponds to a variably expressed alterna-
tive exon [1,3], which we verified was not expressed in H358 cells (data
not shown). By immunostaining, we also verified that induced ZEB-1
was localized in the nuclei (FigureW2A). Surprisingly, ZEB-1 induction
was heterogeneous among cells within the same island (Figure W2B),
and we noted that the cells expressing the highest levels of ZEB-1 protein
were precisely those that had lost E-Cadherin staining (Figure W2B).
These controls confirm that induced ZEB-1 is in the right cellular com-
partment and is functional.
Chromatin immunoprecipitation assays were performed for ZEB-1
binding in vivo (Figure 4C ). In H358 cells, which express abundant
E-Cadherin, ZEB-1 binding to the E-Cadherin promoter was not de-
tected as assessed by quantitative real-time PCR. However, on ZEB-1
induction, enrichment of E-Cadherin promoter sequences in the im-
munoprecipitate was strongly increased (19-fold). There was no en-
richment of Alu sequences (used as a negative control) with ZEB-1
induction. Similarly, in the absence of Dox, there was no binding of
endogenous ZEB-1 to the SEMA3F E-box sites, whereas on ZEB-1
induction, binding to sites 1 and 4 was significantly increased (4-
and 2.2-fold enrichment, respectively), although not to the same de-
gree that we observed with E-Cadherin.
Values obtained in ChIP experiments for ZEB-1 binding on E-
Cadherin and SEMA3F were different in H661 and H358 cells. More
ZEB-1 bound on the E-Cadherin promoter than on the SEMA3F
promoter in H358 cells (Figure 4C ), whereas the opposite was found
in H661 cells (Figure 3B). We cannot exclude that when modifying
the endogenous level of a transcription factor, organization of regula-
tory complexes could be changed. In addition, H358 and H661 cells
could present differences in their repertoire of transcriptional regula-
tors. Epigenetic modifications in E-Cadherin and SEMA3F regulatory
sequences in H358 and H661 cells could explain different accessibil-
ity to ZEB-1.
SEMA3F Loss Is Associated with Cell Signaling
Changes in H661 Cells
We recently reported that SEMA3F overexpression reduced HIF-
1α protein in hypoxia in three cell lines (H157 and H460 lung cancer
cells and COS cells) [14]. Because ZEB-1 represses SEMA3F in H661
cells, we asked whether SEMA3F inhibition by siRNA would lead to
the opposite effect. We first verified SEMA3F inhibition by siRNA
(Figure 5A). Then, HIF-1α protein levels were monitored after treat-
ing the cells with the hypoxia mimetic, CoCl2. As shown in Figure 5B,
HIF-1α levels were higher when SEMA3F was inhibited compared
to control or to mock-transfected cells (Figure 5B). Furthermore,
phospho-AKTwas increased in normoxia when SEMA3F was inhib-
ited (Figure 5B). These results demonstrate that SEMA3F repression
has functional consequences on cell signaling.
ZEB-1–Induced Angiogenesis Is Reduced
by Exogenous SEMA3F
In addition to direct effects on tumor cells, SEMA3F has been re-
ported to be a potential antiangiogenic protein [11–14]. Because
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ZEB-1 inhibits SEMA3F, we wondered whether ZEB-1 induction
would increase angiogenesis. This was tested using a chick CAM as-
say. Uninduced or Dox-induced H358 FlpIn ZEB-1 cells in Matrigel
plug were implanted into the CAMs. Six days after implantation, the
presence and orientation of newly formed blood vessels were evaluated
(Figure 5, C andD). With uninduced cells, little angiogenesis was ob-
served, whereas a significant angiogenic response was noticed when
ZEB-1 was induced. However, this angiogenic response was reduced
when recombinant SEMA3F was added in the plug. Therefore, we
conclude that ZEB-1 induction is associated with increased angio-
genesis that can be at least partially overcome by SEMA3F.
Discussion
SEMA3F impairs tumor formation in several xenograft models
and has been shown to be an antiangiogenic and antimetastatic mol-
ecule [11–15]. Because of its tumor suppressor activity and its loss of
expression in human lung cancers, it is important to understand how
SEMA3F expression is regulated. Screening 21 NSCLC cell lines by
quantitative real-time RT-PCR revealed a significant inverse correla-
tion between SEMA3F and ZEB-1 expression suggesting that this E-
box transcriptional repressor negatively regulates SEMA3F. To verify
this model, we chose H661 lung cancer cells in which we previously
demonstrated E-Cadherin down-regulation by ZEB-1 [20]. In the
present study, we found that transiently transfected ZEB-1 decreased
SEMA3F expression. On the contrary, when ZEB-1 was inhibited by
siRNA, the expression of both SEMA3F and E-Cadherin was en-
hanced. With the presence of four conserved putative E-box sites
in SEMA3F, we performed ChIP assays and found that two of these
(site 1 in the CpG island and site 4 in intron 3) bound ZEB-1 (sum-
mary in Figure W1A). In addition, treatment with SAHA (vorino-
stat), an HDACi, increased SEMA3F expression and decreased
ZEB-1 binding to these two sites, without affecting ZEB-1 expres-
sion. To verify that ZEB-1 binds SEMA3F in another lung cancer cell
line, we performed ChIP assays in ZEB-1–inducible H358 FlpIn
cells. As in H661 cells, ZEB-1 bound to sites 1 and 4 (Figure W1A)
and reduced SEMA3F mRNA. Because site 1 is bipartite, composed
of a CACCTG and CAGGTG sequence separated by 104 nucleo-
tides, we mutated each site separately or together and observed in-
creased expression using a luciferase reporter assay in H661 cells.
Together, these results demonstrate that ZEB-1 is capable of repressing
SEMA3F in lung cancer cells by directly binding to conserved E-box
sites in the 5′region of the gene.
Snail, another E-box binding factor, which regulates the induction
of EMT, is known to induce ZEB-1 expression by directly binding to
ZEB-1 promoter [37]. Snail is induced by VEGF [38], and this induc-
tion involves suppression of the glycogen synthase kinase-3 after bind-
ing of VEGF to neuropilin in breast cancer cells [39]. Interestingly, in
a microarray analysis, SEMA3F was downregulated in Snail-induced
Figure 4. ZEB-1 binds directly to SEMA3F in ZEB-1–induced H358 cells. (A) H358 FlpIn EV or FlpIn ZEB-1 were treated (+) or not (−) with
Dox for 3 days, and ZEB-1, SEMA3F, and E-Cadherin mRNA levels were determined by quantitative real-time RT-PCR. Values, for three
independent experiments with each RT-PCR in duplicate, are expressed in percentage of GAPDH expression. Bars, SD. (B) ZEB-1 over-
expression was checked by Western blot analysis in H358 FlpIn EV or FlpIn ZEB-1 induced by Dox in the same conditions as (A) with two
different antibodies against Myc (as ZEB-1 is Myc-tagged) and ZEB-1. α-Tubulin was used as a loading control. (C) Chromatin immuno-
precipitation assays were done with the ZEB-1 antibody on H358 FlpIn ZEB-1 cells grown 3 days in the absence (black bars) or in the
presence (white bars) of Dox. E-Cadherin and Alu PCR primers, respectively, were used as positive and negative ChIP controls. Values
for three independent experiments are expressed as those in Figure 3. Bars, SD. Statistical analysis was performed with Student’s t-test:
*P < .05, **P < .01.
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colon cancer cells [40]. In agreement with the down-regulation of
SEMA3F by ZEB-1, we observed that Snail overexpression simulta-
neously induced ZEB-1 and repressed SEMA3F in H358 cells (data
not shown). These data suggest that Snail indirectly regulates SEMA3F
through ZEB-1 in these cells, although our studies do not rule out the
possibility that Snail could also regulate the SEMA3F promoter perhaps
at different stages of lung cancer development or progression.
We previously reported that SEMA3F, when overexpressed, re-
duced phospho-AKT in normoxia and HIF-1α protein in hypoxia
in several cell lines. In this study, we demonstrated that SEMA3F
loss in another cell line (H661 cells) has the opposite effect. We also
report, in a CAM assay, that SEMA3F is able to modulate the angio-
genic activity induced by ZEB-1. To our knowledge, angiogenic ac-
tivity of ZEB-1 has not been previously reported. Because Snail and
E47-expressing MDCK induced angiogenesis by the host stromal tis-
sue in a transplantation assay [41] and angiogenic-related genes such
as Jagged1 (JAG1) were upregulated in these cells [42], there is a pre-
cedent for ZEB-1 to have a similar effect. In addition, the consequences
of SEMA3F loss and previous data published by us and others after
SEMA3F overexpression suggest that loss of SEMA3F confers survival
to tumor cells and is involved in angiogenesis.
As discussed earlier, ZEB-1 regulates the induction of EMT, which
plays a critical role in tumor progression and invasion leading to me-
tastasis [26]. Loss of E-Cadherin is one hallmark of EMT. E-Cadherin
is a cell surface transmembrane protein that plays a major role in epi-
thelial cell adhesion and connects the extracellular environment to
the contractile cytoskeleton. Interestingly, E-Cadherin inhibition has
been shown to result in a gradual EMTin A431 cells, although changes
in E-box transcription factors were not reported [43]. Impaired
E-Cadherin expression or function can alter the pattern of cell growth,
differentiation, and invasiveness influencing survival in patients with
cancer [22,44,45]. In lung cancer, we reported that expression of
ZEB-1 and the loss of E-Cadherin correlate with resistance to gefitinib
(an EGFR inhibitor), and with a poor prognosis [21,22]. We pre-
viously noted that MCF7 breast cancer cells, when treated with con-
ditioned medium as a source of SEMA3F, reduced their contacts with
delocalized E-Cadherin and β-catenin [46]. Therefore, we examined E-
Cadherin expression and localization in islands of SEMA3F-induced
Figure 5. Physiological effects of SEMA3F loss. (A, B) H661 cells were transfected with siRNA against SEMA3F (siSEMA3F) or nontar-
geting siRNA (siCTL). Control was mock-transfected cells. (A) SEMA3F mRNA was monitored by quantitative real-time RT-PCR 48 hours
after transfection. Values for three independent experiments, done in duplicate, are expressed in percentage of GAPDH expression.
Bars, SD. (B) H661 cells were transfected by siRNA in absence or presence of 100 μM CoCl2 during 2 hours, and effects on signaling
were monitored by Western blot analysis for HIF-1α, phospho-Ser473-AKT, and total AKT. α-Tubulin was used as a loading control. (C)
Chorioallantoic membrane assays were performed to test angiogenesis. H358 FlpIn ZEB-1 cells were treated or not with Dox and then
loaded on chick embryos in Matrigel with either presence or absence of recombinant SEMA3F-Fc. Six days after implantation, angio-
genesis was evaluated independently by two observers with scores ranging from 0 to 3 as shown in D (scale, 3 mm). Using a nonpara-
metric Kruskal-Wallis test, scores were significantly different with ZEB-1–induced cells versus noninduced cells (***P < .001) and
ZEB-1–induced cells versus ZEB-1–induced cells plus SEMA3F (**P < .01). Bars, mean. n, number of eggs.
164 SEMA3F Semaphorin/Lung Cancer/ZEB-1/Gene Regulation Clarhaut et al. Neoplasia Vol. 11, No. 2, 2009
H358-FlpIn cells. We observed both E-Cadherin and SEMA3F label-
ing at the membrane without E-Cadherin loss of intensity (Fig-
ure W3). The different results obtained with MCF7 and H358 cells
might be explained by the different intrinsic adhesive properties of
the two cell lines, the use of SEMA3F-conditioned medium (exocrine
effects) versus induction (autocrine effects) or by the differences in the
signaling response to SEMA3F [14]. Interestingly, very recently we
transfected ZEB-1 into MCF7 cells (these cells express high levels of
endogenous SEMA3F and almost no ZEB-1). ZEB-1 was induced to a
level similar to that of H661 lung cancer cells. However, we did not
notice any difference in SEMA3Fand E-Cadherin expression (data not
shown) suggesting that in MCF7 cells, SEMA3F and E-Cadherin are
not direct ZEB-1 targets or that a ZEB-1 coregulator/partner is absent
in these cells. Therefore, there is some evidence that SEMA3F regula-
tion and signaling involve different mechanisms in MCF7 breast can-
cer cells than in lung cancer cells.
In H661 cells, we found that HDAC inhibition was associated with
ZEB-1 dissociation from its binding sites in E-Cadherin and SEMA3F,
allowing the expression of these two genes that play a critical role in the
inhibition of tumor development or progression. Similar effects with
SAHA on transcription factor binding were reported for Myc and the
p21 promoter in multiple myeloma cells [47]. Also, butyrate and tri-
chostatin A led to decreased Sp1 and increased Sp3 binding to the
major vault protein promoter in Hep3B cells [48], and trichostatin
A nearly abolished TF-κB binding to the human tissue factor promoter
in endothelial cells and monocytes [49]. Also, induction of TRAIL
by HDACi was associated with the down-regulation of promoter-
associated enzymes and acetylation of resident and de novo recruitment
of Sp1 and Sp3 [50].
To our knowledge, SEMA3F represents the second tumor suppres-
sor gene in lung cancer affected by ZEB-1 in addition to E-Cadherin.
SEMA3F has been shown by us and others to have potent antitumor
effects, and loss of E-Cadherin is associated with a poor prognosis
and resistance to EGFR inhibitors. Together, these data indicate that
ZEB-1 plays a critical role in the biology of lung cancer and repre-
sents an important therapeutic target.
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Supplementary Material and Methods
Immunofluorescence
Cultured cells on glass coverslips were stained by an indirect immuno-
fluorescence method. Cells were rinsed in PBS and fixed with 3.7%
formaldehyde in PBS for 10 minutes at room temperature. They
were permeabilized with PBS plus 0.5% Triton X-100 for 5 minutes.
Cells were treated overnight at 4°C, with PBS containing 1% BSA to
block nonspecific binding sites. They were then incubated with pri-
mary antibodies: rabbit anti–ZEB-1 (1:50; Santa Cruz Biotechnology)
ormouse anti–E-Cadherin (1:100; BDBiosciences) in PBS for 2 hours
at room temperature. The same anti–ZEB-1 antibodies were used
for Western blot analysis and ChIP assay. After three washes with
PBS, 5 minutes at room temperature, cells were incubated for 30 min-
utes with goat antirabbit IgG conjugated to the fluorescent Alexa
488 dye (1:400; Invitrogen Molecular Probe, Leiden, Netherlands)
or with goat antimouse IgG conjugated to the fluorescent Alexa 555
dye (1:400; Invitrogen Molecular Probe) in PBS containing the fluores-
cent nuclear probes TOPRO3 (1:250; Invitrogen Molecular Probe).
After three washes, samples were mounted in Vectashield Medium
(Vector Laboratories Inc, Abcys, Paris, France) for viewing with a con-
focal microscope (FV 1000, Olympus IX-81, Tokyo, Japan).
Table W1. Primer Sequences for Real-time Quantitative RT-PCR (A), ChIP assays (B), ZEB-1 and SEMA3F siRNA (C), E-box Site–Directed Mutagenesis (D), and Luciferase Reporter Construct with
Restriction Sites Underlined (E).
Primer Name Primer Sense Primer Sequence (5′–>3′) Amplicon Size (bp)
(A) Real-time quantitative RT-PCR primers
GAPDH Forward TGCACCACCAACTGCTTAGC 87
Reverse GGCATGGACTGTGGTCATGAG
SEMA3F Forward AGCAGACCCAGGACGTGAG 114
Reverse AAGACCATGCGAATATCAGCC
E-Cadherin Forward CGGGAATGCAGTTGAGGATC 201
Reverse AGGATGGTGTAAGCGATGGC
ZEB-1 Forward AGCAGTGAAAGAGAAGGGAATGC 226
Reverse GGTCCTCTTCAGGTGCCTCAG
ZEB-2 Forward AGGCATATGGTGACGCACAA 78
Reverse CTTGAACTTGCGGTTACCTGC
(B) ChIP primers
ChIP E-Cadherin Forward GGCCGGCAGGTGAACCCTCA 108
Reverse GGGCTGGAGTCTGAACTGA
A Forward GGCGTATGGATGTGTGGATGA 90
Reverse TATGAGAGCACCCACCCAGAAC
B Forward GATTCTGAAGGTGGCAATGCC 100
Reverse AAACTTCCAGCTCCGCCTCTA
C Forward GGAGCCCATGAGGATAACCAA 86
Reverse CCGTAAGCCTCCTTCCTCACA
D Forward TGTGCCTCGGTTTCTCCATC 89
Reverse CCCCTTCACAACACCCACC
E Forward TTGATGCTGTTGCGTACCCTG 99
Reverse CACCCAAAGCTAAACCCCTGA
F Forward CCCTACAGTTCCAGCAGCCC 90
Reverse CCACCAACCCAGACCCTGAT
(C) Primer sequences for ZEB-1 silencing by RNA interference
ZEB-1 Sense AATGCAGATTGAGGCTGATCACCTGTCTC
Antisense AATGATCAGCCTCAATCTGCACCT GTCTC
SEMA3F genome smart pool M-0176644-02 (Dharmacon) GAACCGAACACACCUGUAU
GCAAGGAUGUCAACGGCGA
CAACACAACCGACUACCGA
GCUGGUGUGUACAUCGAUU
(D) Site-directed mutagenesis primers
E-Box mut1 Forward GAAGGGGGTGCTTATATTAGCGCAGGCTCGTTGCTC
Reverse GAGCAACGAGCCTGCGCTAATATAAGCACCCCCTTC
E-Box2 mut2 Forward GGGGCTGCACCGCCATTACCTGAGCAGCCCGGG
Reverse CCCGGGCTGCTCAGGTAATGGCGGTGCAGCCCC
(E) Primers for luciferase reporter construct
XhoI-5836 Forward GCGCTCGAGCTCAGCAGGATCCCTAGTGCC
4013-HindIII Reverse GTTAAGCTTGCACTCACCTCTTCCGCAG
Figure W1. Summary of ZEB-1 binding sites in SEMA3F in H661 and H358 FlpIn ZEB-1 cells. (A) E-Box sites that bound ZEB-1 are
indicated by black stars (sites 1 and 4), whereas those invalidated are in white (sites 2 and 3). The enrichment factors are given for
H661 cells without or with HDAC inhibition by SAHA and for H358 FlpIn ZEB-1 cells without or with ZEB-1 induction by Dox. Percentage
of input for the ChIP experiments in H661 cells without or with SAHA (B; left and right, respectively) and in H358 cells (C) without (−Dox)
or with (+Dox).
Figure W2. Induced ZEB-1 is localized in the nuclei of H358 FlpIn ZEB-1 cells and is present in cells where E-Cadherin is reduced. (A)
Immunostaining with ZEB-1 antibody in H358 FlpIn EV or FlpIn ZEB-1 cells induced or not by Dox was performed to check the locali-
zation of ZEB-1. Nuclei were stained with the TOPRO3 probe. Three independent experiments were done. (B) Immunostaining with anti–
E-Cadherin and anti–ZEB-1 antibodies was done in H358 FlpIn ZEB-1 cells induced or not with Dox. This experiment was done twice.
Figure W3. E-Cadherin localization is not modified by SEMA3F in H358 cells. Myc-tagged SEMA3F cDNA was cloned into pcDNA5/FRT/
TO (Invitrogen) at the EcoRV site and introduced into H358 FlpIn cells. SEMA3F was induced for 3 days with Dox at 200 ng/ml. Cells
were fixed with 3.7% formaldehyde for 20 minutes. Immunostaining with anti–E-Cadherin and anti-Myc antibodies was done with or
without induction. Nuclei were stained with the TOPRO3 probe.
